1st R&D Training Day in Biopharmaceuticals and Medical Devices

Thumbnail

Event details

Date 22.03.2017
Hour 08:3017:30
Speaker Brigitte Happ, PhD    Regulatory Affairs, Happ-Consulting, Merck, Serono, Giba-Geigy
Kostas Kaloulis, PhD    Business Development & Entrepreneurship, EPFL, LifeCare Partners, ReMedys, NsGene, Merck, Apoxis
Mariagrazia di Marco, PhD    Medical Devices and Clinical Research, HUG, Nanobiotix, Guerbet
Tiziana Mattioni, PhD    Precinical & Clinical Development, Consulting, Genenta, Merck, Serono
Sonia Poli, PhD    Biopharma R&D, Poli Consulting, Dimerix, Addex, Roche
Elisabeth Svanberg, PhD-MD    Clinical and Product Development, Ixaltis, Janssen, J&J, BMS  
Location
Category Internal trainings

Are you interested on how to translate research into society useful applications
Then you are invited by the School of Life Sciences and the Applied Innovation Mechanism (AIM) at the VP Innovation to this 1-day course.
6 Industry Experts will discuss, and give you an overview, on how to Pave the Path from Researchto Product Development.
Limited Places
TO REGISTER PLEASE FILL IN THIS DOODLE: http://doodle.com/poll/2y5sbewhz8nzm7p7
Goal: This course aims to introduce key topics of drug and medical devices development  and medical devices
Learning objectives: At the end of the course, the participant will be able to understand:
·         the main principles of clinical development for Drugs and Devices
·         the border between a drug and a medical device
·         how to translate a project from bench to bed
·         the importance of Good Clinical Practice
·         the importance of project oversight
·         the role of regulatory affairs in drug development
·         the importance health authority engagement
·         key elements required for partnering and licensing
Learning methods: Lectures, case studies

About AIM: AIM’s ambition is to Provide; funding, R&D Industry expertise and network, business development/Planning support and industrial network, entrepreneurship in residence, to help validating technologies and identifying potential industry partners, or other “exits”, to advance these technologies to the marketplace.
AIM’s primary goal is to advance technologies to the inflection point where additional funding from industry and/or technology transfer is feasible or achieved.
AIM’s vision is to evolve, in alignment with all relevant stake holders, into the 1st Innovation Incubator supporting all schools at EPFL.
AIM is an initiative designed to accommodate all tools and expertise into supporting projects of varying magnitude, and area.
AIM pilot is currently supporting several projects at the School of Life Sciences.